TY - JOUR
T1 - Hospital-acquired pneumonia is more frequent and lethal in stroke patients
T2 - A nationwide 4-year study
AU - Gonçalves-Pereira, João C.
AU - Marino, Flavio
AU - Mergulhão, Paulo
AU - Nunes, Baltazar
AU - Froes, Filipe
N1 - Funding Information:
This work was supported by a research grant from Merck, Sharp, and Dohme, a division of Merck (IIS no. 58769) under the Investigator Studies Program.
Funding Information:
Dr Gonçalves-Pereira reports an unrestricted research grant from Merck, Sharp, and Dohme for this study and personal fees from Merck Sharp and Dohme and Biomerieux for lectures at medical events outside the submitted work during the past 36 months. He is currently the nonpaid president of the Portuguese Infection and Sepsis Group (Grupo de Infecção e Sepsis, www.gis.pt ). This group has received financial support during the past 36 months from the following sources: Merck, Sharp, and Dohme; Pfizer; BioMérieux in support of a medical education initiative regarding the use of antibiotics; Astellas, Accelerate Diagnostics; Maquet; Baxter; Gilead; Pfizer; and Merck, Sharp, and Dohme in support of the Infection and Sepsis International Symposium organization. Dr Mergulhão reports personal fees for lectures at medical events from Merck, Sharp, and Dohme; Pfizer; BioMérieux; and Accelerate Diagnostics. He also reports nonfinancial support from Merck, Sharp, and Dohme for attending a medical meeting outside of the submitted work during the past 36 months. Dr Froes reports an unrestricted research grant from Merck, Sharp, and Dohme for this study as well as personal fees for lectures at medical events from Pfizer; Merck, Sharp, and Dohme; Gilead; Novartis; Bial; Sanofi; AstraZeneca; Tecnifar; Glaxo Smith Kline; Bayer; Lilly; Roche; and Boehringer Ingelheim outside the submitted work. During the past 36 months, he has received nonfinancial support from Merck, Sharp, and Dohme; Pfizer; Gilead; and Sanofi for attending medical meetings as well as personal fees for serving on advisory boards for Merck, Sharp, and Dohme and Sanofi.
Publisher Copyright:
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.
PY - 2023/1/29
Y1 - 2023/1/29
N2 - We report a higher incidence of hospital-acquired pneumonia (HAP) in patients admitted with stroke (odds ratio, 5.6; 95% CI, 5.4-5.8). Patients with HAP and stroke had an elevated risk of death (odds ratio, 1.2; 95% CI, 1.1-1.3). The incidence and mortality of HAP in stroke patients increased across all age groups.
AB - We report a higher incidence of hospital-acquired pneumonia (HAP) in patients admitted with stroke (odds ratio, 5.6; 95% CI, 5.4-5.8). Patients with HAP and stroke had an elevated risk of death (odds ratio, 1.2; 95% CI, 1.1-1.3). The incidence and mortality of HAP in stroke patients increased across all age groups.
UR - http://www.scopus.com/inward/record.url?scp=85116558939&partnerID=8YFLogxK
U2 - 10.1017/ice.2021.398
DO - 10.1017/ice.2021.398
M3 - Article
AN - SCOPUS:85116558939
SN - 0899-823X
VL - 44
SP - 122
EP - 124
JO - Infection Control and Hospital Epidemiology
JF - Infection Control and Hospital Epidemiology
IS - 1
ER -